Compare ABRDN Physical Gold Shares ETF (SGOL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ABRDN Physical Gold Shares ETF trades at $41.91, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| SGOL | VRTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $529.65 |
52-Week Low | $31.61 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL, a US-listed gold ETF, trades at $41.35, up 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rebound potential, driven by central bank buying and dovish Fed expectations. The stock shows strong support at $41 and resistance at $42, with institutional sentiment leaning positive amid macroeconomic support for precious metals.
Outlook remains cautiously optimistic as gold benefits from lower real yields and geopolitical factors, though overbought conditions near-term pose a risk. Investment appeal hinges on sustained macroeconomic trends, while volatility from dollar movements and profit-taking presents challenges for short-term holders.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
